Search results
Heart Disease in Pregnancy: Maternal and Neonatal Risk
Added:
1 month ago
Original Research
Added:
1 year ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an…
View more
Added:
1 year ago
In this video, Dr Marta Kałużna-Oleksy is joined by Dr Mirvat Alasnag, Dr Shrilla Banerjee and Dr Michal Hawranek to discuss strategies for heart failure management, based on a presentation at the Prevention and Intervention meeting in 2024.The faculty discuss SCAD, MINOCA and holistic approaches to managing these conditions, including lifestyle factors, hypertension and diabetes. They outline…
View more
Obesity in Focus
Added:
5 months ago
Video
Added:
9 months ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,…
View more
Added:
2 years ago
What is hot at ESC 2023?
In this episode of View of the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, NL) preview the hot line and late-breaking data presented at ESC Congress 2023.
With their dynamic analysis, they place these highly anticipated trials within a context, highlighting the real-world implications tied to the data releases.
Top trials…
View more
Added:
2 years ago
ESC 2023 — Dr Ramón Luengo-Fernández (University of Oxford, UK) joins us on-site to discuss the findings from a registry which aimed to analyse the economic burden of cardiovascular disease within the EU.
This was the first study to utilise Europe-wide patient registries and included the costs of long-term social care. Results from the registry found that cardiovascular disease cost the EU €282…
View more
Added:
2 years ago
AHA 2023 - Investigator, Dr A Michael Lincoff (Cleveland Clinic, US) is interviewed by Dr Ahmed Ghoneem (UPMC Harrisburg, US), CardioNerds Ambassador, on the findings of the SELECT Trial (NCT03574597).SELECT is a randomised trial aiming to determine if semaglutide can reduce the risk of cardiovascular events in patients with overweight or obesity and prior cardiovascular disease. 17609 patients…
View more
Added:
1 year ago
ACC 2024 — Late-breaker host, Dr Harriette Van Spall and Principal Investigator, Dr C Michael Gibson discuss the AEGIS-II trial (CSL Behring) (NCT03473223).This phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study investigated the efficacy and safety of an apolipoprotein A-I (apoA-I), CSL112 in patients with acute coronary syndrome (ACS). Investigators enrolled…
View more
Added:
2 years ago
In this week's Parallax, Dr Ankur Kalra welcomes back Dr Sukhjinder Nijjer for their much-anticipated annual review of advancements in cardiovascular medicine that defined the year 2023.Dr Nijjer, a Consultant Cardiologist in the UK, serves as the President of the Royal Society of Medicine and is an Honorary Senior Clinical Lecturer at Imperial College London.Drs Kalra and Nijjer share their…
View more